Portal de Periódicos da CAPES

Can the revised IPSS predict response to erythropoietic-stimulating agents in patients with classical IPSS low or intermediate-1 MDS?

2013; Elsevier BV; Volume: 122; Issue: 13 Linguagem: Inglês

10.1182/blood-2013-07-512442

1528-0020

Valeria Santini, Jennifer Schemenau, Alessandro Levis, Enrico Balleari, Rosa Sapena, Lionel Adès, Agnès Guerci, Odile Beyne‐Rauzy, Marie‐Pierre Gourin, Stéphane Chèze, Aspasia Stamatoullas, Alessandro Sanna, Daniela Gioia, Gianni Cametti, Dario Ferrero, Emmanuel Raffoux, Christian Rosé, Antonella Poloni, Thomas Prébet, Laurence Legros, Shanti Natarajan‐Amé, Pierre Fenaux, Ulrich Germing, François Dreyfus, Sophie Park,

Hematological disorders and diagnostics

To the editor: The “classical” International Prognostic Scoring System (IPSS), based on cytogenetics, marrow blast percentage, and number of cytopenias, has played a major role in prognosis assessment in myelodysplastic syndromes (MDS).[1][1] The recently published revised IPSS (IPSS-R), using